Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

ClinicalTrials.gov ID: NCT00146328

Public ClinicalTrials.gov record NCT00146328. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.

Study identification

NCT ID
NCT00146328
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
997 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2001 (Type not available)
Primary completion
May 2008 (Actual)
Completion
Not listed
Last update posted
Mar 6, 2014

Started 2001

United States locations

U.S. sites
86
U.S. states
29
U.S. cities
59
Facility City State ZIP Site status
1182.17.39 MDS Pharma Services Phoenix Arizona — —
1182.17.75 Boehringer Ingelheim Investigational Site Phoenix Arizona — —
1182.17.89 Boehringer Ingelheim Investigational Site Berkeley California — —
1182.17.60 Boehringer Ingelheim Investigational Site Fountain Valley California — —
1182.17.106 Boehringer Ingelheim Investigational Site Los Angeles California — —
1182.17.15 Boehringer Ingelheim Investigational Site Los Angeles California — —
1182.17.40 Tower ID Medical Los Angeles California — —
1182.17.46 Boehringer Ingelheim Investigational Site Los Angeles California — —
1182.17.47 University of Southern California Los Angeles California — —
1182.17.73 Boehringer Ingelheim Investigational Site Los Angeles California — —
1182.17.114 Boehringer Ingelheim Investigational Site San Diego California — —
1182.17.128 Boehringer Ingelheim Investigational Site San Diego California — —
1182.17.37 Boehringer Ingelheim Investigational Site San Francisco California — —
1182.17.58 Boehringer Ingelheim Investigational Site San Francisco California — —
1182.17.96 Boehringer Ingelheim Investigational Site San Francisco California — —
1182.17.87 Boehringer Ingelheim Investigational Site Norwalk Connecticut — —
1182.17.112 Boehringer Ingelheim Investigational Site Washington D.C. District of Columbia — —
1182.17.43 Boehringer Ingelheim Investigational Site Washington D.C. District of Columbia — —
1182.17.65 Boehringer Ingelheim Investigational Site Washington D.C. District of Columbia — —
1182.17.126 Boehringer Ingelheim Investigational Site Fort Lauderdale Florida — —
1182.17.8 Boehringer Ingelheim Investigational Site Fort Myers Florida — —
1182.17.131 Boehringer Ingelheim Investigational Site Miami Florida — —
1182.17.22 Boehringer Ingelheim Investigational Site Miami Florida — —
1182.17.64 Boehringer Ingelheim Investigational Site Orlando Florida — —
1182.17.129 Boehringer Ingelheim Investigational Site Sarasota Florida — —
1182.17.51 Boehringer Ingelheim Investigational Site South Miami Florida — —
1182.17.125 Boehringer Ingelheim Investigational Site Tampa Florida — —
1182.17.132 Boehringer Ingelheim Investigational Site Tampa Florida — —
1182.17.76 Boehringer Ingelheim Investigational Site Tampa Florida — —
1182.17.52 Boehringer Ingelheim Investigational Site Vero Beach Florida — —
1182.17.77 Boehringer Ingelheim Investigational Site Atlanta Georgia — —
1182.17.69 Boehringer Ingelheim Investigational Site Macon Georgia — —
1182.17.136 Boehringer Ingelheim Investigational Site Chicago Illinois — —
1182.17.70 Boehringer Ingelheim Investigational Site Chicago Illinois — —
1182.17.36 Boehringer Ingelheim Investigational Site Evanston Illinois — —
1182.17.1 Boehringer Ingelheim Investigational Site Indianapolis Indiana — —
1182.17.32 University of Kansas School of Medicine - Wichita Wichita Kansas — —
1182.17.102 Boehringer Ingelheim Investigational Site Lexington Kentucky — —
1182.17.21 Boehringer Ingelheim Investigational Site Louisville Kentucky — —
1182.17.30 Boehringer Ingelheim Investigational Site Portland Maine — —
1182.17.67 Boehringer Ingelheim Investigational Site Baltimore Maryland — —
1182.17.86 Boehringer Ingelheim Investigational Site Bethesda Maryland — —
1182.17.111 Boehringer Ingelheim Investigational Site Boston Massachusetts — —
1182.17.63 Boehringer Ingelheim Investigational Site Boston Massachusetts — —
1182.17.74 Boehringer Ingelheim Investigational Site Springfield Massachusetts — —
1182.17.4 Boehringer Ingelheim Investigational Site Ann Arbor Michigan — —
1182.17.115 Boehringer Ingelheim Investigational Site Detroit Michigan — —
1182.17.6 Boehringer Ingelheim Investigational Site Detroit Michigan — —
1182.17.62 Boehringer Ingelheim Investigational Site Kansas City Missouri — —
1182.17.59 Boehringer Ingelheim Investigational Site Las Vegas Nevada — —
1182.17.118 Early Intervention Program (EIP) Clinic Camden New Jersey — —
1182.17.93 Boehringer Ingelheim Investigational Site East Orange New Jersey — —
1182.17.24 Hackensack University Medical Center Hackensack New Jersey — —
1182.17.34 ID Care, Inc. Hillsborough New Jersey — —
1182.17.50 Boehringer Ingelheim Investigational Site Santa Fe New Mexico — —
1182.17.79 Boehringer Ingelheim Investigational Site Albany New York — —
1182.17.103 Boehringer Ingelheim Investigational Site Mount Vernon New York — —
1182.17.105 Pollari Medical Group New York New York — —
1182.17.130 Boehringer Ingelheim Investigational Site New York New York — —
1182.17.3 Division of Infectious Diseases New York New York — —
1182.17.42 Beth Israel Medical Center New York New York — —
1182.17.5 Boehringer Ingelheim Investigational Site New York New York — —
1182.17.7 Boehringer Ingelheim Investigational Site New York New York — —
1182.17.94 Boehringer Ingelheim Investigational Site New York New York — —
1182.17.135 Boehringer Ingelheim Investigational Site Rochester New York — —
1182.17.31 Boehringer Ingelheim Investigational Site Stony Brook New York — —
1182.17.53 Boehringer Ingelheim Investigational Site Durham North Carolina — —
1182.17.54 Boehringer Ingelheim Investigational Site Huntersville North Carolina — —
1182.17.134 Summa Health System Akron Ohio — —
1182.17.95 Boehringer Ingelheim Investigational Site Cincinnati Ohio — —
1182.17.26 Boehringer Ingelheim Investigational Site Columbus Ohio — —
1182.17.9 Boehringer Ingelheim Investigational Site Oklahoma City Oklahoma — —
1182.17.110 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania — —
1182.17.99 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania — —
1182.17.23 Boehringer Ingelheim Investigational Site Columbia South Carolina — —
1182.17.11 Boehringer Ingelheim Investigational Site Memphis Tennessee — —
1182.17.18 Vanderbilt AIDS Clinical Trials Center Nashville Tennessee — —
1182.17.116 Boehringer Ingelheim Investigational Site Dallas Texas — —
1182.17.142 Boehringer Ingelheim Investigational Site Dallas Texas — —
1182.17.16 Nelson-Tebedo Clinic Dallas Texas — —
1182.17.122 Boehringer Ingelheim Investigational Site Houston Texas — —
1182.17.68 Boehringer Ingelheim Investigational Site Houston Texas — —
1182.17.97 Boehringer Ingelheim Investigational Site San Antonio Texas — —
1182.17.10 Boehringer Ingelheim Investigational Site Annandale Virginia — —
1182.17.92 Boehringer Ingelheim Investigational Site Tacoma Washington — —
1182.17.100 Boehringer Ingelheim Investigational Site Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 147 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00146328, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 6, 2014 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00146328 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →